Biopharmaceutical company Gilead Sciences NASDAQ:GILD reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.2% year on year to $7.80 billion. On the other hand, the company’s full-year revenue guidance of $30.25 billion at the midpoint came in 0.6% below analysts’ e…
Biopharmaceutical company Gilead Sciences NASDAQ:GILDwill be reporting earnings this Tuesday after market hours. Here’s what to expect.Gilead Sciences beat analysts’ revenue expectations last quarter, reporting revenues of $6.96 billion, up 4.4% year on year. It was a slower quarter for the company…
Gilead Sciences, Inc. (NASDAQ:GILD) will report Q2 2026 results Aug. 4 with a 4:30 PM ET webcast as data show its ISL/LEN weekly and PURPOSE twice‑yearly lenacapavir regimens sustain viral suppression and adherence, while EMA backs Trodelvy+Keytruda for PD‑L1+ TNBC, EU decision due 2026.Previous We…
Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and Descovy for prevention.The company’s HIV business continues to maintain momentum, driven by solid performances of Biktarvy and Descovy, and incremental contributions from Yeztug…
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2…
(12:33 GMT) Gilead Sciences Price Target Cut to $156.00/Share From $157.00 by Truist Securities
Vertex Pharmaceuticals NASDAQ:VRTX has agreed to buy Crinetics Pharmaceuticals NASDAQ:CRNX for about $10 billion, expanding its reach beyond blood disorders and pain into rare endocrine diseases.The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical…
Gilead Sciences, Inc. GILD recently won FDA approval for the label expansion of breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).Trodelvy, a first-in-class T…
Gilead Sciences Price Target Maintained With a $155.00/Share by Cantor Fitzgerald
By Mariam Sunny and Jennifer RigbyA treatment trial for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo enrolled its first patient on Thursday, marking a milestone in efforts to combat the epidemic, WHO chief Dr. Tedros Adhanom Ghebreyesus told reporters.Tedros, however, cited an…
By Mariam Sunny and Jennifer RigbyA treatment trial for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo enrolled its first patient on Thursday, marking a milestone in efforts to combat the epidemic, WHO chief Dr. Tedros Adhanom Ghebreyesus told reporters.Tedros, however, cited an…
The Africa Centres for Disease Control and Prevention on Tuesday called for $18 million in urgent funding to support trials of experimental Ebola treatments in the Democratic Republic of Congo, warning that delays could jeopardize efforts to contain the outbreak.The appeal comes as clinical trials…
